PetVivo Holdings Inc (PETV) - Cash Flow Conversion Efficiency
Based on the latest financial reports, PetVivo Holdings Inc (PETV) has a cash flow conversion efficiency ratio of -0.438x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.63 Million) by net assets ($3.73 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See PetVivo Holdings Inc (PETV) balance sheet quality index to measure how much of total assets are equity-financed.
PetVivo Holdings Inc - Cash Flow Conversion Efficiency Trend (2011–2025)
This chart illustrates how PetVivo Holdings Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check PetVivo Holdings Inc earnings quality ratio to evaluate the quality of earnings relative to operating cash generation.
PetVivo Holdings Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of PetVivo Holdings Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Success Transformer Corporation Bhd
KLSE:7207
|
0.015x |
|
Ortoma AB Series B
ST:ORT-B
|
-0.120x |
|
Radana Bhaskara Finance Tbk
JK:HDFA
|
-0.240x |
|
Concraft Holding Co Ltd
TW:4943
|
0.011x |
|
Wisr Ltd
AU:WZR
|
0.105x |
|
Jinli Group Holdings Ltd
TW:8429
|
0.000x |
|
CoAsia Corporation
KQ:045970
|
0.073x |
|
Big Camera Corporation Public Company Limited
BK:BIG
|
-0.016x |
Annual Cash Flow Conversion Efficiency for PetVivo Holdings Inc (2011–2025)
The table below shows the annual cash flow conversion efficiency of PetVivo Holdings Inc from 2011 to 2025. For the full company profile with market capitalisation and key ratios, see PetVivo Holdings Inc (PETV) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-03-31 | $4.22 Million | $-5.32 Million | -1.261x | +88.34% |
| 2024-03-31 | $685.95K | $-7.42 Million | -10.816x | -15.42% |
| 2023-03-31 | $725.02K | $-6.79 Million | -9.371x | -1243.82% |
| 2022-03-31 | $5.99 Million | $-4.17 Million | -0.697x | -159.73% |
| 2021-03-31 | $-896.98K | $-1.05 Million | 1.168x | +143.63% |
| 2020-03-31 | $-1.04 Million | $-496.59K | 0.479x | -45.02% |
| 2019-03-31 | $-844.82K | $-736.45K | 0.872x | +120.57% |
| 2018-03-31 | $136.65K | $-579.15K | -4.238x | -2329.30% |
| 2017-03-31 | $819.75K | $-143.02K | -0.174x | -284.41% |
| 2016-03-31 | $15.21 Million | $-690.33K | -0.045x | +98.16% |
| 2015-03-31 | $161.25K | $-398.48K | -2.471x | -440.34% |
| 2014-03-31 | $-301.81K | $-219.13K | 0.726x | +90.00% |
| 2013-03-31 | $-184.51K | $-70.51K | 0.382x | +37.56% |
| 2012-03-31 | $-177.62K | $-49.34K | 0.278x | -87.92% |
| 2011-03-31 | $-74.99K | $-172.42K | 2.299x | -- |
About PetVivo Holdings Inc
PetVivo Holdings, Inc., a biomedical device company, manufactures, commercializes, and licenses medical devices and therapeutics for animals in the United States. The company's lead product is Spryng, a veterinarian-administered, intraarticular injection for the management of lameness and other joint afflictions, such as osteoarthritis in dogs and horses. It also provides therapeutic devices for … Read more